Full Press Release Details
argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease.
ZLAB
argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease
Key Takeaway: argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease
Price reaction · baseline $17.77 (2025-12-12 close) · clean, no other ZLAB news in the window
day 0 close · peak
-2.4%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+60%
120-day peak, hindsight
Typical move
2.2%
average across 15 past catalysts
Cash runway
~28 mo
Low dilution risk
Lead asset
ZL-1310
Phase 3 · Small-cell Lung Cancer